228 related articles for article (PubMed ID: 27062540)
1. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
2. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
[TBL] [Abstract][Full Text] [Related]
3. Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease.
Yablecovitch D; Oren A; Ben-Horin S; Fudim E; Eliakim R; Saker T; Konikoff FM; Kopylov U; Matthias T; Lerner A
Dig Dis Sci; 2017 Mar; 62(3):755-760. PubMed ID: 28025744
[TBL] [Abstract][Full Text] [Related]
4. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
Szarvas T; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky I; Rübben H
Hum Pathol; 2014 Apr; 45(4):674-82. PubMed ID: 24656090
[TBL] [Abstract][Full Text] [Related]
5. Serum and tissue syndecan-1 levels in renal cell carcinoma.
Niedworok C; Kempkensteffen C; Eisenhardt A; Tschirdewahn S; Rehme C; Panic A; Reis H; Baba H; Nyirády P; Hadaschik B; Kovalszky I; Szarvas T
Transl Androl Urol; 2020 Jun; 9(3):1167-1176. PubMed ID: 32676400
[TBL] [Abstract][Full Text] [Related]
6. Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.
Niedworok C; Tschirdewahn S; Reis H; Lehmann N; Szücs M; Nyirády P; Romics I; Rübben H; Szarvas T
Pathol Oncol Res; 2017 Jul; 23(3):643-650. PubMed ID: 28012116
[TBL] [Abstract][Full Text] [Related]
7. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
8. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
9. Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.
Bruce HM; Stricker PD; Gupta R; Savdie RR; Haynes AM; Mahon KL; Lin HM; Kench JG; Horvath LG
Prostate; 2016 Dec; 76(16):1491-1500. PubMed ID: 27473574
[TBL] [Abstract][Full Text] [Related]
10. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
[TBL] [Abstract][Full Text] [Related]
11. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy.
Arslan B; Onuk Ö; Hazar İ; Aydın M; Çilesiz NC; Eroglu A; Nuhoglu B
Tumori; 2017 Mar; 103(2):204-208. PubMed ID: 27470607
[TBL] [Abstract][Full Text] [Related]
14. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
15. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.
Santos NJ; Barquilha CN; Barbosa IC; Macedo RT; Lima FO; Justulin LA; Barbosa GO; Carvalho HF; Felisbino SL
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445387
[TBL] [Abstract][Full Text] [Related]
16. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
20. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
